Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Anne S Strik, Sophie E Berends & Mark Löwenberg. (2019) Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Review of Clinical Pharmacology 12:9, pages 885-891.
Read now
Read now
Gregor Novak, Pieter Hindryckx, Reena Khanna, Vipul Jairath & Brian G. Feagan. (2017) The safety of vedolizumab for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 16:4, pages 501-507.
Read now
Read now
Nikola Mitrev & Rupert W. Leong. (2017) Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opinion on Drug Safety 16:3, pages 303-317.
Read now
Read now
Articles from other publishers (35)
Teresa Valdés-Delgado, Alicia Aguado-Paredes, Vicente Merino-Bohórquez, Jesús Martín-Manzanares, María Mercedes Alonso, Belén Maldonado, Luisa Castro, María Belvis, Beatriz Benítez, Ángel Caunedo, Miguel Ángel Calleja & Federico Argüelles-Arias. (2023) Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA. Digestive Diseases and Sciences.
Crossref
Crossref
Hui-Jun Tang, Cai-Qun Bie, Li-Liangzi Guo, Li-Xian Zhong & Shao-Hui Tang. (2023) Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta‑analysis of randomized controlled trials. Experimental and Therapeutic Medicine 25:6.
Crossref
Crossref
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong & Daniel R. van Langenberg. (2023) Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. Journal of Gastroenterology and Hepatology 38:5, pages 724-732.
Crossref
Crossref
Adam Makaro, Mikołaj Świerczyński, Kacper Pokora, Barbara Sarniak, Radzisław Kordek, Jakub Fichna & Maciej Salaga. (2023) Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis. Inflammopharmacology.
Crossref
Crossref
Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim & Jae Hee Cheon. (2022) Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases. Scientific Reports 12:1.
Crossref
Crossref
A. Nassar-Sheikh Rashid, D. Schonenberg-Meinema, S. C. Bergkamp, S. Bakhlakh, A. de Vries, T. Rispens, T. W. Kuijpers, G. Wolbink & J. M. van den Berg. (2021) Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). Pediatric Rheumatology 19:1.
Crossref
Crossref
Geoffrey S. Haar, Abhinav Vasudevan, Colin M. Curtain & Daniel R. van Langenberg. (2021) Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. Research in Social and Administrative Pharmacy 17:8, pages 1420-1425.
Crossref
Crossref
Ashish Srinivasan, Peter De Cruz & Daniel R van Langenberg. (2021) Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach. Gut 70:4, pages 812-813.
Crossref
Crossref
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay & Patricio Ibañez. (2021) Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología 44:4, pages 312-319.
Crossref
Crossref
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay & Patricio Ibañez. (2021) Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 44:4, pages 312-319.
Crossref
Crossref
Pepijn W. A. Thomas, Paul K. L. Chin & Murray L. Barclay. (2021) A nationwide survey on therapeutic drug monitoring of anti‐tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal 51:3, pages 341-347.
Crossref
Crossref
Pavel Svoboda & Tomáš Kupka. (2020) Infliximab pharmacokinetics monitoring in inflammatory bowel disease. Vnitřní lékařství 66:8, pages e34-e38.
Crossref
Crossref
Elise M van Praag, Merel E Stellingwerf, Jarmila D W van der Bilt, Wilhelmus A Bemelman, Krisztina B Gecse & Christianne J Buskens. (2020) Ligation of the Intersphincteric Fistula Tract and Endorectal Advancement Flap for High Perianal Fistulas in Crohn’s Disease: A Retrospective Cohort Study. Journal of Crohn's and Colitis 14:6, pages 757-763.
Crossref
Crossref
Isabel Pinto Pais, Maria C. Espinheira, Eunice Trindade & Jorge Amil Dias. (2020) Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. Journal of Pediatric Gastroenterology & Nutrition 71:1, pages 12-18.
Crossref
Crossref
Ashish Srinivasan, Daniel R. van Langenberg, Robert D. Little, Miles P. Sparrow, Peter De Cruz & Mark G. Ward. (2020) A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease. Alimentary Pharmacology & Therapeutics 51:12, pages 1342-1352.
Crossref
Crossref
Mario RegazziJoseè Golay & Mariadelfina Molinaro. (2020) Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. Therapeutic Drug Monitoring 42:1, pages 45-56.
Crossref
Crossref
Daniela Pugliese, Giuseppe Privitera, Fabrizio Pizzolante, Antonio Gasbarrini, Luisa Guidi & Alessandro Armuzzi. (2020) Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterologica e Dietologica 65:4.
Crossref
Crossref
Omoniyi J. Adedokun, Zhenhua Xu, Sam Liao, Richard Strauss, Walter Reinisch, Brian G. Feagan & William J. Sandborn. (2020) Population Pharmacokinetics and Exposure–Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clinical Therapeutics 42:1, pages 157-174.e4.
Crossref
Crossref
Murray L. Barclay, Shwan Karim, Esther T. Johanna Helms, Paula E. Keating, Barry Hock, Lisa K. Stamp & Michael Schultz. (2019) Infliximab and adalimumab concentrations and anti‐drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal 49:4, pages 513-518.
Crossref
Crossref
Ashish Srinivasan, Nik Sheng Ding, Daniel van Langenberg & Peter De Cruz. 2019. Biomarkers in Inflammatory Bowel Diseases. Biomarkers in Inflammatory Bowel Diseases
243
255
.
Alexandre Jentzer, Anne-Emmanuelle Berger, Rémi Labetoulle, Alice Haccourt, Xavier RoblinStephane Paul. (2018) Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar. Therapeutic Drug Monitoring 40:6, pages 749-753.
Crossref
Crossref
José Luis Martín-Varillas, Vanesa Calvo-Río, Emma Beltrán, Juan Sánchez-Bursón, Marina Mesquida, Alfredo Adán, María Victoria Hernandez, Marisa Hernández Garfella, Elia Valls Pascual, Lucía Martínez-Costa, Agustí Sellas-Fernández, Miguel Cordero-Coma, Manuel Díaz-Llopis, Roberto Gallego, David Salom, Norberto Ortego, José L. García-Serrano, José-Luis Callejas-Rubio, José M. Herreras, Ángel García-Aparicio, Olga Maíz, Ana Blanco, Ignacio Torre, David Díaz-Valle, Esperanza Pato, Elena Aurrecoechea, Miguel A. Caracuel, Fernando Gamero, Enrique Minguez, Carmen Carrasco-Cubero, Alejandro Olive, Julio Vázquez, Oscar Ruiz-Moreno, Javier Manero, Santiago Muñoz-Fernández, Myriam Gandía Martinez, Esteban Rubio-Romero, F. Javier Toyos-Sáenz de Miera, Francisco Javier López Longo, Joan M. Nolla, Marcelino Revenga, Carmen González-Vela, Javier Loricera, Belén Atienza-Mateo, Rosalía Demetrio-Pablo, José Luis Hernández, Miguel A. González-Gay & Ricardo Blanco. (2018) Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology 125:9, pages 1444-1451.
Crossref
Crossref
Xavier Roblin, Céline Vérot, Stéphane Paul, Gérard Duru, Nicolas Williet, Gilles Boschetti, Emilie Del Tedesco, Laurent Peyrin-Biroulet, Jean Marc Phelip, Stéphane Nancey & Bernard Flourie. (2018) Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. Inflammatory Bowel Diseases 24:9, pages 2078-2085.
Crossref
Crossref
Sophie Restellini, Che-yung Chao, Peter L Lakatos, Achuthan Aruljothy, Haya Aziz, Omar Kherad, Alain Bitton, Gary Wild, Waqqas Afif & Talat Bessissow. (2018) Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab. Inflammatory Bowel Diseases 24:7, pages 1531-1538.
Crossref
Crossref
F. Magro, C. Rocha, A. I. Vieira, H. T. Sousa, I. Rosa, S. Lopes, J. Carvalho, C. C. Dias & J. Afonso. (2018) The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels. Therapeutic Advances in Gastroenterology 11, pages 175628481879695.
Crossref
Crossref
Allison Guttmann, Svetlana Krasnokutsky, Michael H. Pillinger & Adey Berhanu. (2017) Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Therapeutic Advances in Drug Safety 8:12, pages 379-388.
Crossref
Crossref
N. Mitrev, N. Vande Casteele, C. H. Seow, J. M. Andrews, S. J. Connor, G. T. Moore, M. Barclay, J. Begun, R. Bryant, W. Chan, C. Corte, S. Ghaly, D. A. Lemberg, V. Kariyawasam, P. Lewindon, J. Martin, R. Mountifield, G. Radford-Smith, P. Slobodian, M. Sparrow, C. Toong, D. van Langenberg, M. G. Ward & R. W. Leong. (2017) Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 46:11-12, pages 1037-1053.
Crossref
Crossref
James O. Lindsay, Alessandro Armuzzi, Javier P. Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C. Nguyen, Michael Smyth & Haridarshan Patel. (2017) Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 49:10, pages 1086-1091.
Crossref
Crossref
Fernando Magro, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Tânia Meira, Patrícia Andrade, João-Bruno Soares, Diana Carvalho, Paula Sousa, Ana Isabel Vieira, Joanne Lopes, Cláudia Camila Dias, Karel Geboes & Fátima Carneiro. (2017) Clinical performance of an infliximab rapid quantification assay. Therapeutic Advances in Gastroenterology 10:9, pages 651-660.
Crossref
Crossref
Joana Afonso, Helena Tavares de Sousa, Isadora Rosa, João Carvalho, Cláudia Camila Dias & Fernando Magro. (2017) Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therapeutic Advances in Gastroenterology 10:9, pages 661-671.
Crossref
Crossref
Yun Qiu, Bai-li Chen, Ren Mao, Sheng-hong Zhang, Yao He, Zhi-rong Zeng, Shomron Ben-Horin & Min-hu Chen. (2017) Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease. Journal of Gastroenterology 52:5, pages 535-554.
Crossref
Crossref
Haridarshan Patel, Trevor Lissoos & David T. Rubin. (2017) Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLOS ONE 12:4, pages e0175099.
Crossref
Crossref
Xiutian Guo, Mao-Gang Li, Shan-Shan Li, Feng-Hua Liu, Zhan-Ju Liu & Ping-Chang Yang. (2017) Tumor necrosis factor suppresses interleukin 10 in peripheral B cells via upregulating Bcl2-like protein 12 in patients with inflammatory bowel disease. Cell Biochemistry and Function 35:2, pages 77-82.
Crossref
Crossref
Marina Kostić, Ljiljan Djakovic, Raša Šujić, Brian Godman & Slobodan M. Janković. (2016) Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Applied Health Economics and Health Policy 15:1, pages 85-93.
Crossref
Crossref
J. Afonso, S. Lopes, R. Gonçalves, P. Caldeira, P. Lago, H. Tavares de Sousa, J. Ramos, A. R. Gonçalves, P. Ministro, I. Rosa, A. I. Vieira, C. C. Dias & F. Magro. (2016) Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Alimentary Pharmacology & Therapeutics 44:7, pages 684-692.
Crossref
Crossref